The requirement for cardiovascular safety trials for T2D therapies ushered in a new evidence-based era for GLP-1 medicines, demonstrating a reduction in myocardial infarction, stroke, cardiovascular death, and all-cause mortality in people with T2D treated with long-acting GLP-1 medicines. The gene discussed is GCG; the disease is stroke disorder.